- Home
- RMR vs ZBIO Comparison
RMR vs ZBIO Comparison
Compare RMR & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMR
- ZBIO
- Stock Information
- Founded
- RMR 1986
- ZBIO 2019
- Country
- RMR United States
- ZBIO United States
- Employees
- RMR N/A
- ZBIO N/A
- Industry
- RMR Professional Services
- ZBIO
- Sector
- RMR Consumer Discretionary
- ZBIO
- Exchange
- RMR Nasdaq
- ZBIO NYSE
- Market Cap
- RMR 347.9M
- ZBIO 339.3M
- IPO Year
- RMR N/A
- ZBIO 2024
- Fundamental
- Price
- RMR $19.76
- ZBIO $7.85
- Analyst Decision
- RMR Buy
- ZBIO Strong Buy
- Analyst Count
- RMR 2
- ZBIO 5
- Target Price
- RMR $32.00
- ZBIO $31.75
- AVG Volume (30 Days)
- RMR 117.6K
- ZBIO 390.2K
- Earning Date
- RMR 02-05-2025
- ZBIO 02-16-2025
- Dividend Yield
- RMR 9.11%
- ZBIO N/A
- EPS Growth
- RMR N/A
- ZBIO N/A
- EPS
- RMR 1.38
- ZBIO N/A
- Revenue
- RMR $196,924,000.00
- ZBIO N/A
- Revenue This Year
- RMR $379.19
- ZBIO N/A
- Revenue Next Year
- RMR $2.01
- ZBIO N/A
- P/E Ratio
- RMR $14.32
- ZBIO N/A
- Revenue Growth
- RMR N/A
- ZBIO N/A
- 52 Week Low
- RMR $19.08
- ZBIO $7.50
- 52 Week High
- RMR $26.82
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- RMR 36.55
- ZBIO N/A
- Support Level
- RMR $19.25
- ZBIO N/A
- Resistance Level
- RMR $20.00
- ZBIO N/A
- Average True Range (ATR)
- RMR 0.50
- ZBIO 0.00
- MACD
- RMR 0.04
- ZBIO 0.00
- Stochastic Oscillator
- RMR 35.98
- ZBIO 0.00
About RMR The RMR Group Inc.
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.